exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087964 RNA Name: hsa-miR-24-3p RNA Type: miRNA Chromosome: chr9 Starnd: + Coordinate: Start Site(bp): 95086064 End Site(bp): 95086085 External Links: hsa-miR-24-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand AEN chr15 88621337 88632281 + AMOTL2 chr3 134355874 134375479 - APPL2 chr12 105173297 105236203 - ARPP19 chr15 52547045 52569883 - CD74 chr5 150400041 150412929 - CEP170B chr14 104865268 104896770 + CGN chr1 151510510 151538692 + CPA4 chr7 130293134 130324180 + CREG1 chr1 167529117 167553805 - CYB5B chr16 69424619 69466264 + DNAJB6 chr7 157335381 157417439 + GALNT10 chr5 154190730 154420984 + GIGYF1 chr7 100679507 100694037 - PLEKHM1 chr17 45435900 45490749 - RUBCN chr3 197668867 197749727 - STK4 chr20 44966479 45080021 + TMEM9 chr1 201134772 201171574 - WDR36 chr5 111091716 111130502 + GSK3B chr3 119821323 120094417 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000402 chr12 53670403 53671011 + hsa_circ_0000155 chr1 168007608 168014465 + hsa_circ_0000733 chr17 1561546 1562030 - lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand A1BG-AS1 chr19 58347718 58355455 + AC005034.3 chr2 75697583 75697996 + AC005394.2 chr19 28435388 28727680 - AC027031.2 chr8 106270144 106272902 + AC079781.5 chr7 97851688 97972985 - AC091564.7 chr11 6610883 6616594 - AL031282.2 chr1 1702736 1737688 - DIO3OS chr14 101552221 101560431 - EBLN3P chr9 37079645 37090928 + KCNQ1OT1 chr11 2608328 2699994 - MCM3AP-AS1 chr21 46229196 46259390 + MIR22HG chr17 1711493 1717174 - MIR497HG chr17 7015818 7019659 - NEAT1 chr11 65422774 65445540 + Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.